02q3

Targeting Trends Newsletter 02q3

Below are links to view the quarterly newsletter Targeting Trends. If you would like to be added to the mailing list, please complete the information on our contact page. Newsletter Highlights Featured Antibodies (page 3 and page 4) Neuropeptide Toxins (page 5) Anti-Tac and Anti-Tac-SAP (page 7) Page 1 Page 5 Page 2 Page 6 Page …

Targeting Trends Newsletter 02q3 Read More »

Targeting Talk: Neuropeptide Toxins

What are neuropeptide-toxins and how do they work? Neuropeptide-toxin conjugates are made up of the ribosome-inactivating protein, saporin, coupled to a naturally-occurring or synthetically-modified neuropeptide such as Substance P or dermorphin. The conjugate has binding specificity similar to the native, unconjugated neuropeptide. When the neuropeptide binds to its cognate receptor, the conjugate is internalized. Once …

Targeting Talk: Neuropeptide Toxins Read More »

Targeting Topics 02q3

Impairments in negative patterning, but not simple discrimination learning, in rats with 192 IgG-saporin lesions of the nucleus basalis magnocellularis. Butt AE, Noble MM, Rogers JL, Rea TE. Behav Neurosci 116(2):241-255, 2002. PMID: 11996310 192-Saporin (Cat. #IT-01) administration to the basal forebrain has frequently been used in rats to create a model for Alzheimer’s disease. …

Targeting Topics 02q3 Read More »

Cover Article: Saporin Immunotoxins for Treating Human Hematological Malignancies

Contributed by David J Flavell, PhD, The Simon Flavell Leukaemia Research Unit, Division of Cancer Sciences, University of Southampton Medical School, United Kingdom. I have asked Dr. Flavell to contribute an article on the clinical use of his saporin immunotoxins. Dr. Flavell’s research unit is named after his son, who died from leukemia. At that …

Cover Article: Saporin Immunotoxins for Treating Human Hematological Malignancies Read More »